MBX Biosciences Appoints Kent Hawryluk as President and Chief Executive Officer

Greg Davis, Ph.D., Appointed as Vice President of Product Development.

Carmel, Ind., Jan. 6, 2020 – MBX Biosciences, a preclinical-stage biotechnology company leveraging world-class peptide drug discovery for rare endocrine diseases, announced today the appointment of Kent Hawryluk to the position of president and chief executive officer. Hawryluk is a co-founder and a member of MBX’s board of directors. Additionally, Greg Davis, Ph.D., has been appointed to the position of vice president, product development.

“We founded MBX with a vision to create a higher standard of care in the treatment of rare endocrine disorders, and I am proud to take this role as we grow,” said Hawryluk. “As we enter 2020, I look forward to working alongside a proven team of drug developers to advance our research.”

“MBX’s leadership team brings together individuals who have collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics,” said Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX Biosciences. “On behalf of MBX’s board of directors, I congratulate Kent on his new role and look forward to his leadership. We also congratulate and welcome Greg Davis to MBX in a key operational role.”

Hawryluk brings to MBX nearly 20 years’ experience founding and building successful life sciences companies. He co-founded Marcadia Biotech and MB2, helping lead both companies to clinical proof-of-concept of potential first-in-class peptide drugs in metabolic disorders and to acquisitions by Roche and Novo Nordisk, respectively. Since January 2003, he has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund. Most recently, he was a co-founder and chief business officer of Avidity Biosciences, a genetic medicines company that has innovated antibody-oligonucleotide conjugates (AOCsTM). Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Hawryluk received his bachelor’s degree from Princeton University, his master’s of business administration from Kellogg School of Management at Northwestern University, and his master’s of science in biology from Purdue University.

Dr. Davis brings to MBX nearly 35 years’ experience in drug development in biotech and pharma. Since June 2017, he has served as chairman of the board of Inotiv, a publicly-traded clinical research organization. Before this, he served as vice president of CMC, regulatory and quality at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, which was sold to Novo Nordisk. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in biotechnology product development, global regulatory affairs, global brand teams, and quality. Dr. Davis received his bachelor’s degree in chemistry from Southeast Missouri State University, and his doctorate in chemistry from Purdue University.

About MBX Biosciences

MBX Biosciences is a biotechnology company using validated molecular targets to create therapies for rare endocrine diseases with inadequate treatment options available today. Members of MBX’s leadership team have collaborated successfully on the discovery, development and commercialization of first-in-class endocrine drugs, including Forteo® and Humalog®. MBX is strengthened by the world-class proprietary peptide drug discovery engine created by Richard DiMarchi, Ph.D., co-founder and chief scientific officer. In September 2019, MBX received seed funding from The Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads), and Twilight Venture Partners II. For more information, please visit mbxbio.com.

Media Contact:
Mari Purpura, Ph.D.
Canale Communications